We previously reported that GSK-3β inhibition sensitizes pancreatic cancer and glioblastoma cells to gemcitabine and temozolomide, respectively, as well as sensitizing them to ionizing radiation through the modulation of distinct molecular pathways [14–17]. This evidence concerns the gene GSK3B and familial pancreatic carcinoma.